Drug intelligence / Profile preview

recombinant SIRT1

Development stage
Preclinical
Modality
Recombinant Proteins and Enzymes
Administration
Intraperitoneal
01

Overview

Recombinant SIRT1 (rSIRT1) is a recombinant protein version of sirtuin 1 (SIRT1), an NAD+-dependent class III histone deacetylase that plays a key role in regulating cellular metabolism, epigenetic gene silencing, inflammation, and aging. By deacetylating histones and non-histone substrates such as p53, PGC-1α, and PCSK9, SIRT1 modulates pathways involved in mitochondrial biogenesis, oxidative stress, and lipid metabolism. In preclinical models, exogenous administration of recombinant SIRT1 has been shown to rescue cardiac function in metabolic cardiomyopathy, improve endothelial function, and reduce LDL-cholesterol levels and plaque progression in atherosclerosis. Recombinant SIRT1 is primarily utilized as a research-use-only (RUO) reagent for biochemical assays, high-throughput screening of SIRT1 modulators, and preclinical in vivo and in vitro studies.

Other names
recombinant human SIRT1recombinant murine SIRT1recombinant sirtuin 1rhSIRT1rhSIRT-1rhSIRT 1rmSIRT1rmSIRT-1rmSIRT 1rSIRT1rSIRT-1rSIRT 1
02

Targets

PCSK9 (Proprotein convertase subtilisin/kexin type 9)PPARGC1A (Peroxisome proliferator–activated receptor gamma coactivator 1-alpha)TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on recombinant SIRT1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant SIRT1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call